Prognosis was most favourable in tumours with >50% of cells expressing FOXJ1 (HR 0.78, 95% CI 0.67–0.91, p < 0.05), with the 5-year survival being >10% higher than those without expression. The gene discussed is FOXJ1; the disease is neoplasm.